Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326752 · ClinicalTrials.gov registry record · Phase 1
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03326752 is a Phase 1 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 26 participants.
The verdict
NCT03326752, a Phase 1 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).
Interventions
- DRUG DV281
- DEVICE Breath Actuated Nebulizer
- DRUG DV281 (RP2D)
- DRUG Approved Anti-PD-1 Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03326752
The ClinicalTrials.gov registry entry for NCT03326752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which DV281 is the first listed.
NCT03326752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03326752 about?
NCT03326752 is a clinical study titled "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC". This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).
What is the current status of trial NCT03326752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-09-20. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03326752?
The interventions under investigation include: DV281 (DRUG), Breath Actuated Nebulizer (DEVICE), DV281 (RP2D) (DRUG), Approved Anti-PD-1 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT03326752?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.